Login to Your Account



Clinic Roundup


Thursday, April 12, 2012
• Threshold Pharmaceuticals Inc., of South San Francisco, received a $20 million milestone payment from Darmstadt, Germany-based Merck KGaA, which was triggered by results from a clinical trial of its drug TH-302 in pancreatic cancer. In the trial comparing TH-302 with gemcitabine to gemcitabine alone in 214 patients, the drug showed a significant benefit for progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription